Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the epidiolex (cannabidiol) market size evolved in recent years?

The market for Epidiolex (cannabidiol) has seen substantial growth in the past few years. It is projected to increase from $3.55 billion in 2024 to $3.89 billion in 2025, with a compound annual growth rate (CAGR) of 9.7%. This surge during the historical period can largely be credited to the emphasis on patient-focused medical therapies, expanding research validating cannabidiol’s potency in controlling epilepsy, heightened patient understanding of potential medicinal benefits of cannabidiol, growing preference for substitutes to traditional anti-epileptic medications, and a worldwide rise in demand for medical cannabis products.

What are the predictions for the epidiolex (cannabidiol) market size in the coming years?

The market size for Epidiolex (cannabidiol) is projected to witness significant expansion in the upcoming years, reaching $5.55 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 9.3%. This anticipated growth during the forecast period can be linked to factors such as the rising number of insurance firms that cover Epidiolex, enhanced understanding of the adverse effects of conventional anti-epileptic drugs, growing demand for herbal, plant-based pharmaceuticals, increasing diagnoses of epilepsy in both children and adults, and supportive governmental regulations and schemes for medicinal cannabis. Key trends predicted for the forecast period encompass the incorporation of cannabidiol into existing treatment routines, advancements in manufacturing technologies, collaboration with healthcare bodies, the incorporation of Epidiolex into treatment strategies for refractory epilepsy, the employment of artificial intelligence in the evolution of cannabidiol products, and the invention of water-soluble cannabidiol for improved bioavailability.

Get your epidiolex (cannabidiol) market report here!

https://www.thebusinessresearchcompany.com/report/epidiolex-cannabidiol-global-market-report

What key factors are fueling the growth of the epidiolex (cannabidiol) market?

The growth of the epidiolex (cannabidiol) market is anticipated to be fueled by the rising number of epilepsy cases. Epilepsy, a neurological disorder characterized by recurrent, unprovoked seizures due to abnormal brain electrical activity, is on the rise. This surge in epilepsy cases can be traced back to improved diagnosis, increased awareness, and the escalating incidence of conditions like brain injuries, stroke, and genetic factors. Epidiolex, a cannabidiol (CBD) derived prescription medication, is used to treat certain forms of epilepsy. It mitigates the frequency and intensity of seizures by regulating the brain’s signaling pathways. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US government agency, reported approximately 2.9 million U.S. adults aged 18 and older had active epilepsy in 2022, roughly 1% of the adult population. In addition, it is estimated that about 456,000 children aged 17 and under in the US have active epilepsy. Consequently, the rise in epilepsy cases will propel the epidiolex (cannabidiol) market.

How is the global epidiolex (cannabidiol) market divided into key segments?

The epidiolex (cannabidiol) market covered in this report is segmented –

1) By Product: Oral Solution, Capsules, Oil Solution

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

3) By Application: Epilepsy Treatment, Dravet Syndrome Treatment, Lennox-Gastaut Syndrome Treatment, Seizure Management

Subsegments:

1) By Oral Solution: Standard Oral Solution, High-Concentration Oral Solution

2) By Capsules: Standard Capsules, Extended-Release Capsules

3) By Oil Solution: Standard Oil Solution, Concentrated Oil Solution

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20777&type=smp

Who are the key firms paving the way for growth in the epidiolex (cannabidiol) market?

Major companies operating in the epidiolex (cannabidiol) market are Cannoid LLC, Jazz Pharmaceuticals Plc, Curaleaf Holdings Inc., Trulieve Cannabis Corp., Cresco Labs Inc., Tilray Brands Inc., Columbia Care Inc., Canopy Growth Corporation, Acreage Holdings Inc., Verano Holdings Corp., Aurora Cannabis Inc., Planet 13 Holdings Inc., The Cronos Group Inc., Folium Biosciences LLC, Green Roads of Florida LLC, Medterra CBD LLC, Endoca B.V., CV Sciences Inc., NuLeaf Naturals LLC, Isodiol International Inc., PharmaHemp d.o.o., Koi CBD LLC, Elixinol Global Limited, Vapen CBD LLC, 180 Life Sciences Corp.

What key trends are currently impacting the epidiolex (cannabidiol) market’s development?

Major companies operating in the epidiolex (cannabidiol) market are focusing on developing innovative products, such as synthetic cannabidiol (CBD) products designed to gain a competitive edge in the market. A synthetic cannabidiol (CBD) product is a lab-manufactured formulation of CBD designed to replicate the therapeutic effects of natural CBD without the presence of tetrahydrocannabinol (THC). For instance, in January 2024, Akumentis Healthcare Ltd., an India-based pharmaceutical company, launched Clasepi, a DCGI-approved synthetic cannabidiol (CBD) product designed to treat seizures associated with lennox-gastaut syndrome (LGS), dravet syndrome, and tuberous sclerosis complex (TSC) in patients aged 1 year and older. It is the first synthetic CBD of its kind to be available in India, with less than 0.1% THC, making it non-psychotropic. Clinical studies have shown that Clasepi is effective in reducing seizures, particularly in cases where traditional antiseizure medications have failed. The product comes with usage guidelines and is not recommended for individuals allergic to cannabidiol or any of its ingredients. Adhering to healthcare providers’ instructions is critical for optimal use and safety.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20777

What regions are contributing significantly to the growth of the epidiolex (cannabidiol) market?

North America was the largest region in the epidiolex (cannabidiol) market in 2024. The regions covered in the epidiolex (cannabidiol) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cannabidiol Global Market Report 2025

https://thebusinessresearchcompany.com/report/cannabidiol-global-market-report

Cannabis Products Global Market Report 2025

https://thebusinessresearchcompany.com/report/cannabis-products-global-market-report

Cannabis Testing Global Global Market Report 2025

https://thebusinessresearchcompany.com/report/cannabis-testing-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: